Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Sinclair Pharma plc

18 Oct 2018 15:15

RNS Number : 4688E
Toscafund Asset Management LLP
18 October 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Toscafund Asset Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Sinclair Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

17 October 2018

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

 

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

0

0

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares

Sale

56,613,603

31.50

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

18 October 2018

Contact name:

Mr. Robert Lord

Telephone number:

0207 845 6100

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETMPBPTMBABMLP
Date   Source Headline
28th Mar 20177:15 amRNSHardman Research: Much more streamlined
27th Mar 201710:30 amRNSAppointment of Joint Broker
22nd Mar 20175:29 pmRNSHolding(s) in Company
21st Mar 20177:00 amRNSPreliminary Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
17th Jan 20179:27 amRNSHardman Research: Demanding targets exceeded
17th Jan 20177:00 amRNSPre-Close Trading Update
5th Jan 20177:15 amRNSNotification of full year trading update
17th Nov 201610:39 amRNSDirector/PDMR Shareholding
17th Nov 201610:36 amRNSAdditional Listing
8th Nov 20169:08 amRNSHardman Research: Poised for a long term uplift
8th Nov 20167:05 amRNSHardman Research: Poised for a long term uplift
18th Oct 20165:55 pmRNSHolding(s) in Company
13th Oct 20164:46 pmRNSHolding(s) in Company
5th Oct 20167:00 amRNSDirector/PDMR Shareholding
3rd Oct 20163:56 pmRNSHolding(s) in Company
30th Sep 20162:29 pmRNSTotal Voting Rights
29th Sep 20162:24 pmRNSHolding(s) in Company
28th Sep 20162:23 pmRNSAdditional Listing
27th Sep 20164:14 pmRNSDirector/PDMR Shareholding
27th Sep 20164:12 pmRNSDirector/PDMR Shareholding
26th Sep 20165:04 pmRNSAdditional Listing
22nd Sep 20162:02 pmRNSHolding(s) in Company
21st Sep 20167:00 amRNSHalf-year Report
1st Sep 20167:00 amRNSRestructuring Programme and Board Change
22nd Aug 20167:00 amRNSNotice of Results
19th Jul 20167:00 amRNSTrading Statement
2nd Jun 20167:00 amRNSPresenting at Jefferies Healthcare Conference
31st May 20167:00 amRNSDirector Dealing
24th May 20169:52 amRNSPurchase of shares by Chief Financial Officer
23rd May 20167:00 amRNSDirector Dealing
20th May 201611:43 amRNSOption Awards
20th May 201610:16 amRNSDirector Dealings
20th May 20167:00 amRNSUS Collaboration and Positive Trading Update
19th May 20164:35 pmRNSUS Collaboration and Positive Trading Update
19th May 20162:15 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th May 201612:50 pmRNSForm 8.3 - Sinclair Pharma PLC
19th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201611:24 amRNSForm 8.3 - Sinclair Pharma plc
17th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
16th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
13th May 20161:35 pmRNSForm 8.3 - Sinclair Pharma plc
12th May 201612:40 pmRNSForm 8.3 - Sinclair Pharma plc
11th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
10th May 20162:13 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
10th May 20161:56 pmRNSForm 8.3 - Sinclair Pharma plc
9th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201611:25 amPRNForm 8.3 - Sinclair Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.